For the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent...
This development underscores the company's commitment to advancing innovative solutions that provide relief and improved quality of life for the millions o...
This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination w...
CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben 18F injection) has ...
This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Additional...
GBM AGILE Adaptive Platform Trial Recruiting in Australia Austin Health in Melbourne and Royal North Shore Hospital in Sydney are Now Enrolling Patients ...
Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfo...
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
In conjunction with breast cancer awareness month, the Malaysia Healthcare Travel Council (MHTC) together with Subang Jaya Medical Centre, organised a thou...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Cardiovascular diseases (CVDs) present a substantial global health concern, and Malaysia, is not immune to this health issue. As reported by the World Heal...
“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...
© 2025 Biopharma Boardroom. All Rights Reserved.
